Navigation Links
Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
Date:1/25/2010

Data Reported at the 2010 ASCO GI Cancers Symposium Demonstrate a Statistically Significant Improvement in Both Time to Tumor Progression and Overall Survival in the Perifosine + Capecitabine Arm Versus Placebo + Capecitabine Arm

QUÉBEC CITY, Jan. 25 /PRNewswire-FirstCall/ - Æterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ) (the "Company"), a late-stage drug development company specialized in oncology and endocrinology, today announced that its partner, Keryx Biopharmaceuticals ( KERX), presented updated results yesterday on the clinical activity of perifosine (KRX-0401), the Company's PI3K/Akt pathway inhibitor for cancer, in combination with capecitabine (Xeloda(R)) as a treatment for advanced, metastatic colon cancer. Abstract #447, entitled, "Randomized Phase II study of perifosine in combination with capecitabine (P-CAP) versus capecitabine plus placebo (CAP) in patients with second- or third-line metastatic colon cancer (mCRC): Updated results", was presented yesterday in a poster during the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, held in Orlando, Florida. Keryx is Æterna Zentaris' partner and licensee for perifosine in the United States, Canada and Mexico. Perifosine is also out-licensed to Handok in South Korea while Æterna Zentaris retains rights for the rest of the world.

Study Design

In this randomized, double-blind, placebo-controlled study conducted at 11 centers across the United States, heavily pre-treated patients with second- or third-line metastatic colon cancer were randomized to receive cape
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Æterna Zentaris Receives NASDAQ Notification Related to Minimum Bid Price
2. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
3. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
4. AEterna Zentaris Announces Appointment of New Board Member
5. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
7. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
8. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
9. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
10. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
11. AEterna Zentaris to Complete Phase 3 Clinical Trial of Macimorelin (AEZS-130) as First Oral Diagnostic Test for Growth Hormone Deficiency
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2014)... 18, 2014 TNI BioTech, Inc. (OTC-BB: TNIB) ... manufacturing and marketing of innovative therapies for autoimmune diseases ... providing a second notice of TNI BioTech,s annual meeting ... announcement, Noreen Griffin , founder and CEO of ... your participation in the Annual Meeting. On behalf of ...
(Date:8/18/2014)... August 18, 2014 China is ... for the clinical research industry. Clinicaltrial.gov statistics highlight ... to its aging population; a high increase in ... a densely populated pool of patients and a ... these positive points, China also presents challenges for ...
(Date:8/16/2014)... 16, 2014 Firms in the ... guidance and advisory services to businesses, government bodies ... Industry services are highly diverse as operators assist ... range from geological and geophysical consulting services to ... the past five years, the recovery of the ...
(Date:8/16/2014)... make atomic-force microscope probes 20 times more sensitive and ... of an individual virus. , The technique, developed by ... using laser beams to cool a nanowire probe to ... achieved after cooling is accurate enough for us to ... 100 billion times lighter than a mosquito," said Dr ...
Breaking Biology Technology:TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 2TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 3TNI BioTech Inc., provides 2nd Notice of Annual Meeting September 4, 2014 4China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 2Scientific and Economic Consulting in Canada Industry Market Research Report Now Available from IBISWorld 3Laser makes microscopes way cooler 2
... Feb. 4 Art,s Way Manufacturing, Inc. (Nasdaq: ... subsidiary, Art,s Way Scientific, Inc. - Buildings For ... - http://www.buildingsforscience.com/ The new site, reflective ... enhanced, clean and more user-friendly.Art,s Way Scientific ( ...
... (Nasdaq: KNDL ) announced today that it will ... closes on Tuesday, Feb. 24, 2009. The Company will host ... 25 at 8:30 a.m. Eastern Time. A question and answer ... participate in the telephone conference call, interested parties in the ...
... Patients Achieved an Objective Tumor Response by End of ... Inc. (Nasdaq: PPHM ) today reported that ... endpoint in the first stage of its ongoing Phase ... cancer (NSCLC). The open-label, Simon two-stage study is ...
Cached Biology Technology:Art's Way Manufacturing Announces Launch of New Web Site For Art's Way Scientific - Buildings For Science 2Art's Way Manufacturing Announces Launch of New Web Site For Art's Way Scientific - Buildings For Science 3Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call 2Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 2Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 3Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study 4
(Date:8/19/2014)... DIEGO, Calif. (August 19, 2014) Daylight was breaking ... MY Hanse Explorer. Between sips, about a dozen scientists ... and slip below the surface to collect water samples ... would tinker with the whirring gizmos and delicate machinery ... single goal: Be the first research group to bring ...
(Date:8/18/2014)... person,s gut may protect against or increase susceptibility to ... bacterial intestinal inflammation, according research published this week in ... American Society for Microbiology. The study also found that ... one,s gut bacteria composition. , "It has been known ... in the gut, can protect a person from colonization ...
(Date:8/18/2014)... UT Southwestern Medical Center have found a new way that ... known as long non-coding RNA. , The internal body clocks, ... functions, from waking and sleeping to body temperature and hunger. ... influenced by external cues such as light and temperature. , ... many organisms, what they do in the body, and how ...
Breaking Biology News(10 mins):Sequencing at sea 2Sequencing at sea 3What's in your gut? Certain bacteria may influence susceptibility to infection 2Researchers obtain key insights into how the internal body clock is tuned 2Researchers obtain key insights into how the internal body clock is tuned 3
... seeking to detect bioterrorism attacks, doctors diagnosing diseases ... a new ally in a Lawrence Livermore National ... as the Lawrence Livermore Microbial Detection Array (LLMDA), ... to detect within 24 hours any virus or ...
... prestigious Pierre Delmas Prize: An ESCEO-IOF/Servier Achievement Award was ... at the Claude Bernard University of Lyon, France. ... honour of the late Pierre D. Delmas, the world ... (IOF). The grant of 40,000 Euros, courtesy of Servier, ...
... A prescription drug already approved to treat genital warts and ... effectiveness of future vaccines for bacterial and viral diseases, such ... appear in ACS, Molecular Pharmaceutics , a bi-monthly journal. ... Research Center and UC-Berkeley note that vaccines prepared from weakened ...
Cached Biology News:New LLNL detection technology identifies bacteria, viruses, other organisms within 24 hours 2New LLNL detection technology identifies bacteria, viruses, other organisms within 24 hours 3Winner of Pierre Delmas Prize announced at World Congress on Osteoporosis 2010 2
Normal human serum, single donor...
... Quality ISO 9001:2000 Certified ... All Precedures Validated, SOP's Training ... Process for All Procedures GLP Documentation Upon ... one stop shopping point for all your ...
Human IL-17D Affinity Purified Polyclonal Ab...
BBS/Glycerol/Casein Block and Diluent - 10X Concentrate, 1 L...
Biology Products: